Drug Information

Drug General Information
Drug ID
D04RCT
Former ID
DCL000751
Drug Name
CHF-3381
Drug Type
Small molecular drug
Indication Neuropathic pain [ICD9: 356.0, 356.8; ICD10:G64, G90.0] Phase 2 [529017], [536374]
Therapeutic Class
Analgesics
Company
Chiesi
Formula
C11H14N2O
Canonical SMILES
C1C(CC2=CC=CC=C21)NCC(=O)N
InChI
1S/C11H14N2O/c12-11(14)7-13-10-5-8-3-1-2-4-9(8)6-10/h1-4,10,13H,5-7H2,(H2,12,14)
InChIKey
MNLULKBKWKTZPE-UHFFFAOYSA-N
PubChem Compound ID
10192617
PubChem Substance ID
15188851, 22585836, 40282178, 75724008, 128621049, 134223472, 134339241, 135261923, 137004968, 143117008, 145860429, 198985653, 225073309, 226728209
SuperDrug ATC ID
L01XX16
SuperDrug CAS ID
cas=000459869
Target and Pathway
Target(s) Amine oxidase [flavin-containing] B Target Info Inhibitor [536374]
NMDA receptor Target Info Antagonist [536374]
Amine oxidase [flavin-containing] A Target Info Inhibitor [536374]
BioCyc Pathway Superpathway of tryptophan utilization
Tryptophan degradation via tryptamine
Dopamine degradation
Putrescine degradation III
Noradrenaline and adrenaline degradationPWY66-401:Superpathway of tryptophan utilization
Noradrenaline and adrenaline degradation
Serotonin degradation
Superpathway of melatonin degradation
Melatonin degradation II
KEGG Pathway Glycine, serine and threonine metabolism
Arginine and proline metabolism
Histidine metabolism
Tyrosine metabolism
Phenylalanine metabolism
Tryptophan metabolism
Drug metabolism - cytochrome P450
Metabolic pathways
Serotonergic synapse
Dopaminergic synapse
Cocaine addiction
Amphetamine addiction
Alcoholismhsa00260:Glycine, serine and threonine metabolism
Alcoholism
NetPath Pathway IL4 Signaling Pathway
PANTHER Pathway Adrenaline and noradrenaline biosynthesis
5-Hydroxytryptamine degredation
Dopamine receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
Dopamine receptor mediated signaling pathway
Pathway Interaction Database Alpha-synuclein signaling
PathWhiz Pathway Histidine Metabolism
Tyrosine Metabolism
Glycine and Serine Metabolism
Reactome Norepinephrine Neurotransmitter Release Cycle
WikiPathways Tryptophan metabolism
Dopamine metabolism
Phase 1 - Functionalization of compoundsWP706:SIDS Susceptibility Pathways
Biogenic Amine Synthesis
Oxidative Stress
Phase 1 - Functionalization of compounds
Neurotransmitter Release Cycle
Neurotransmitter Clearance In The Synaptic Cleft
Serotonin Transporter Activity
References
Ref 529017Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. IDrugs. 2007 Sep;10(9):636-44.
Ref 536374Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
Ref 536374Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.